Related references
Note: Only part of the references are listed.Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: A case-control study
Sayumi Baba et al.
BMC WOMENS HEALTH (2011)
Hyponatraemia induced by low-dose intravenous pulse cyclophosphamide
Young-Chul Lee et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Efficacy and Adverse Events of Mycophenolate Mofetil Versus Cyclophosphamide for Induction Therapy of Lupus Nephritis Systematic Review and Meta-Analysis
Nanticha Kamanamool et al.
MEDICINE (2010)
Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS)
Corine Ekhart et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2007)
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients
Miki Nakajima et al.
PHARMACOGENETICS AND GENOMICS (2007)
Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry
TF Kalhorn et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2006)
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies
HJ Xie et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Clinical pharmacokinetics of cyclophosphamide
ME de Jonge et al.
CLINICAL PHARMACOKINETICS (2005)
Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N′,N-triethylenethiophosphoramide (thiotepa) and N,N′,N-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry
ME de Jonge et al.
JOURNAL OF MASS SPECTROMETRY (2004)
Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients
JJ Liu et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2004)
Cyclophosphamide: new approaches for systemic lupus erythematosus
M Petri
LUPUS (2004)
Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS
BK Matuszewski et al.
ANALYTICAL CHEMISTRY (2003)
Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation
GB McDonald et al.
BLOOD (2003)
Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome P450 genes by ciprofloxacin
HJ Xie et al.
BONE MARROW TRANSPLANTATION (2003)
Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma
L Griskevicius et al.
THERAPEUTIC DRUG MONITORING (2002)
Liquid chromatography-tandem mass spectrometric quantitation of cyclophosphamide and its hydroxy metabolite in plasma and tissue for determination of tissue distribution
N Sadagopan et al.
JOURNAL OF CHROMATOGRAPHY B (2001)
Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography
ADR Huitema et al.
JOURNAL OF CHROMATOGRAPHY B (2000)
Share Paper
